Related Experiment Video
Updated: Oct 12, 2025
13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
14.2K
Urinary Isoxanthopterin in Heart Failure Patients
Masakazu Hori1, Teruhiko Imamura1, Naoya Kataoka1
1Second Department of Internal Medicine, University of Toyama Toyama Japan.
Circulation Reports
|November 22, 2021
Summary
Urinary isoxanthopterin (U-IXP), a marker of oxidative stress, predicts adverse outcomes in decompensated heart failure patients. Higher U-IXP levels correlate with increased cardiovascular death and heart failure readmissions.
Area of Science:
- Biochemistry
- Cardiology
- Biomarkers
Background:
- Oxidative stress plays a role in heart failure pathophysiology.
- Urinary isoxanthopterin (U-IXP) is a novel marker of oxidative stress.
- The prognostic value of U-IXP in heart failure is not well-established.
Purpose of the Study:
- To investigate the prognostic impact of urinary isoxanthopterin (U-IXP) in patients with decompensated heart failure.
- To determine if U-IXP concentration predicts cardiovascular death or heart failure readmissions.
Main Methods:
- Prospective study of 42 patients admitted for decompensated heart failure.
- Measurement of urinary isoxanthopterin (U-IXP) on admission.
- Association analysis between U-IXP levels and a composite outcome of cardiovascular death and heart failure readmissions.
Main Results:
- Median U-IXP concentration was 0.58 μmol/g creatinine.
- Higher U-IXP levels were an independent predictor of the primary outcome.
- A U-IXP cut-off of 0.93 μmol/g creatinine identified patients with significantly higher adverse event rates (71% vs. 16%, P=0.001).
Conclusions:
- Urinary isoxanthopterin (U-IXP) on admission is associated with adverse cardiovascular outcomes in decompensated heart failure.
- U-IXP may serve as a valuable prognostic biomarker in heart failure management.
- Further research is needed to explore interventions targeting U-IXP and its precise role in heart failure progression.
More Related Videos
09:16Highly Sensitive Measurement of Glomerular Permeability in Mice with Fluorescein Isothiocyanate-polysucrose 70
Published on: August 9, 2019
7.1K
08:51Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts
Published on: May 12, 2019
6.9K
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
53
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
53
01:11Renal Failure: Dose Adjustments
190
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
190
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
82
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
82
01:22Heart Failure Drugs: Diuretics
523
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
523
01:30Heart Failure V: Medical Management
47
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
47
01:30Heart Failure VII: Nursing Interventions
183
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
183